Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Hims & Hers Health, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
HIMS · NYSE · Healthcare · Drug Manufacturers Specialty and Generic
$19.730.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Hims & Hers sells prescription treatments and non-prescription health products to consumers, mainly through online subscriptions paired with remote consultations from licensed clinicians.
Company outlook: revenue of $875M to $895M for Fiscal Q4 2026 — up 43.2% on a year earlier